Autolus Therapeutics Plc · NASDAQ:AUTL
Autolus Therapeutics — Q1 2026 Earnings Presentation
11 slides from Autolus Therapeutics's earnings presentation, May 14, 2026
Slide 1: Q1 2026 Financial Results and Business Updates
Q1 2026 Financial Results and Business Updates May 14, 2026 For Investor communication only. Not for use in product promotion. Not for further distribution. Autolus.com
Slide 2: Disclaimer
Developing and Delivering a New Generation of T Cell Therapies Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical fact
Slide 3: Agenda
Developing and Delivering a New Generation of T Cell Therapies Agenda • Welcome and Introduction: Amanda Cray, ED, Investor Relations & External Communications • Operational Highlights: Dr. Christian Itin, CEO • Financial Results: Rob Dolski, CFO • Upcoming Milestones and Conclusion: Dr. Christian I
Slide 4: AUCATZYL is gaining traction in US and UK markets
Developing and Delivering a New Generation of T Cell Therapies AUCATZYL® is gaining traction in US and UK markets AUCATZYL Global Net Product Revenue 2026 Expectations Q1 2026: $26.2 million FY 2026 Net Product Revenue: $120-$135 million Increase commercial footprint in the US to more than 80 treatm
Slide 5: Path to profitability in the ALL business
Developing and Delivering a New Generation of T Cell Therapies Path to profitability in the ALL business Optimizing the operating model and driving cost efficiency Cost reduction initiatives aimed at driving Peak: expect gross profit gross profit margin improvements margin of 65-70% Actions expected
Slide 6: Pipeline-in-a-product: expanding obe-cel's potential beyond adult B-ALL
Developing and Delivering a New Generation of T Cell Therapies Pipeline-in-a-product: expanding obe-cel's potential beyond adult B-ALL Indication Trial Status CATULUS Phase 2 expansion enrolling; data expected at end of 2027 Pediatric r/r B-ALL Phase 1/2 Aligned with FDA on protocol design to suppor
Slide 7: Financial Results
Financial Results
Slide 8: Financial summary – key metrics
Developing and Delivering a New Generation of T Cell Therapies Financial summary – key metrics* USD ($’ 000) Q1 2026 Q1 2025 Variance Product revenue, net 26,218 8,982 17,236 Cost and operating expenses: Cost of sales (24,568) (17,951) (6,617) Research and development expenses, net (21,210) (26,734)
Slide 9: Upcoming news flow
Upcoming news flow
Slide 10: Upcoming milestones
Developing and Delivering a New Generation of T Cell Therapies Upcoming milestones Anticipated Milestone or Catalyst Anticipated Timing Longer-term follow up data from CARLYSLE trial Year End 2026 Initial clinical data from BOBCAT Phase 1 trial in progressive MS Year End 2026 Initial clinical data f
Slide 11: Thank you
Thank you Autolus.com